Get the latest tech news
French biotech Generare speeds up hunt for new drugs by cloning natural molecules
French biotech startup Generare has closed a €5 million seed round (around $5.5 million at current exchange rates) to step up development of what it touts
But finding less common molecules that could become the basis for new antibiotics, anticancer or other drugs requires a new kind of approach that can sift through large amounts of genetic material, says Generare co-founder and chief science officer Dr Vincent Libis. Founded in October 2022, the startup says it’s devised a technique that relies upon cloning and biosynthetics to break up the genetic material of microorganisms into millions of fragments to allow for speedier analysis — making it much quicker and easier to identify new molecules of interest. With so many molecules lurking somewhere out there waiting to be discovered, Generare doesn’t sound worried about competitors raiding nature’s treasures before its had a chance to apply its high scale sifting methodology.
Or read this on TechCrunch